Cost-Utility Analysis of High-Intensity Statins; Atorvastatin 40 and 80 mg versus Rosuvastatin 20 mg from Egyptian Public Payer’s Perspective: A Markov Model
Background: Dyslipidemia is a significant burden correlated with the risk of developing cardiovascular morbidity and mortality. However, no available studies compare the cost-utility analysis of high-intensity statins for managing Egyptian patients with dyslipidemia. The study aimed to measure the c...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wolters Kluwer Medknow Publications
2026-03-01
|
| Cyfres: | International Journal of Preventive Medicine |
| Pynciau: | |
| Mynediad Ar-lein: | https://journals.lww.com/ijom/fulltext/2026/05140/cost_utility_analysis_of_high_intensity_statins_.2.aspx |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|